Glyburide as effective as insulin for gestational diabetes
Glyburide is as effective as insulin for women with gestational diabetes mellitus and a fasting plasma glucose of 140 mg/dL or less on a 3-hour glucose tolerance test, according to a 4-year retrospective study of a large and diverse managed-care population.
Glyburide is as effective as insulin for women with gestational diabetes mellitus and a fasting plasma glucose of 140 mg/dL or less on a 3-hour glucose tolerance test, according to a 4-year retrospective study of a large and diverse managed-care population.
Researchers found certain differences though. Women treated with insulin tended to have a higher mean body mass index, more of them were white and fewer were Asian, and they had a significantly higher mean fasting level on a glucose tolerance test, compared with the women in the glyburide group. While there were no significant differences in birthweight, macrosomia, or cesarean delivery, neonates of women receiving glyburide were more likely to receive phototherapy and less likely to be admitted to the neonatal intensive care unit, but had a longer stay in the NICU if they were admitted.
More women in the glyburide group achieved mean fasting and postprandial goals than did women in the insulin group.
Early preterm birth risk linked to low PlGF levels during pregnancy screening
November 20th 2024New research highlights that low levels of placental growth factor during mid-pregnancy screening can effectively predict early preterm birth, offering a potential tool to enhance maternal and infant health outcomes.
Read More
Major congenital malformations not linked to first trimester tetracycline use
November 20th 2024A large population-based study found that first-trimester tetracycline exposure does not elevate the risk of major congenital malformations, though specific risks for nervous system and eye anomalies warrant further research.
Read More
No link found between prenatal cannabis use and childhood developmental delay
November 5th 2024In a recent study, offspring of women with cannabis use in early pregnancy confirmed by self-report or toxicology test were not at an increased risk of childhood early developmental delay up to the age of 5.5 years.
Read More
Prenatal cannabis use not linked to offspring ASD development
November 1st 2024In a recent study, adjustments for maternal characteristics mediated the association between maternal prenatal cannabis use and offspring autism spectrum disorder, indicating no statistically significant increase in risk.
Read More
